Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 5/20 | 0.43 |
| ▸ | ADH1C | P00326 | 4/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503176 | 1.00 | ADH1A (0.43) | ADH1AADH1CADH1BSHBGMEN1 | |
| SCHEMBL104547 | 0.98 | ADH1A (0.40) | ADH1AADH1CADH1BSHBGMEN1 | |
| SCHEMBL12890106 | 0.95 | ADH1A (0.37) | ADH1AADH1CADH1B | |
| SCHEMBL12744952 | 0.87 | — | — | |
| SCHEMBL20445569 | 0.84 | — | — | |
| SCHEMBL13301673 | 0.83 | ADH1A (0.45) | ADH1AADH1CADH1BSHBGMEN1 | |
| SCHEMBL17914492 | 0.82 | ADH1A (0.41) | ADH1AADH1CADH1BSHBGMEN1 | |
| SCHEMBL6337808 | 0.82 | ADH1A (0.41) | ADH1AADH1CADH1BSHBGMEN1 | |
| SCHEMBL17914487 | 0.82 | ADH1A (0.47) | ADH1AADH1CADH1BSHBGMEN1 | |
| SCHEMBL13503186 | 0.80 | SLC6A2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131271-A1 | PYRROLE FUSED-RING PYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| WO-2007025009-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | ADH1A 3029/4885ADH1C 2213/4885ADH1B 4128/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | ADH1A 4327/4885ADH1C 4366/4885ADH1B 4431/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | ADH1A 1620/4885ADH1C 659/4885ADH1B 396/4885 |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADH1A 577/4885ADH1C 2208/4885ADH1B 649/4885 |
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | ADH1A 3056/4885ADH1C 3227/4885ADH1B 935/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | ADH1A 3486/4885ADH1C 3864/4885ADH1B 4195/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | ADH1A 278/4885ADH1C 247/4885ADH1B 1968/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | ADH1A 1620/4885ADH1C 659/4885ADH1B 396/4885 |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | PREP, PEPD, DPP4 | ADH1A 1234/4885ADH1C 403/4885ADH1B 1321/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | ADH1A 4043/4885ADH1C 4615/4885ADH1B 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.